Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tubacin** is a highly potent, selective, reversible, and cell-permeable small molecule inhibitor of **histone deacetylase 6 (HDAC6)**. Tubacin increases acetylation of α-tubulin without significantly affecting histone acetylation, thereby influencing processes such as microtubule dynamics, intracellular transport, and protein degradation. It has a strong antiproliferative and pro-apoptotic effect in various cancer cell lines, and enhances the effects of other anticancer drugs. Tubacin is primarily used as a research chemical probe for HDAC6 due to its poor drug-like properties, including high molecular weight and lipophilicity, which limit in vivo utility[2][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tubacin.